Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Adjuvant endocrine therapy adherence in breast cancer patients diagnosed in Iceland 2013-2018].

Laeknabladid·2026
Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026
Same author

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Atrial Fibrillation, Anticoagulants, and CRC Outcomes: A Nationwide 20-Year Study.

Thrombosis and haemostasis·2026
Same author

Splenic hamartoma in two related patients with BAP1 tumour predisposition syndrome caused by a novel germline BAP1 p.(Gly128Arg) missense variant.

Familial cancer·2026
Same author

Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report.

Immunotherapy·2025

Related Experiment Video

Updated: Dec 24, 2025

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K

Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing.

Katherine Vlessis1, Natasha Purington1, Nicolette Chun1

  • 1See the Notes section for the full list of authors' affiliations.

JNCI Cancer Spectrum
|April 8, 2020
PubMed
Summary

Many patients with somatic BRCA1/2 mutations do not receive recommended germline testing. This highlights a need for broader provider education on genetic testing guidelines for BRCA-related cancers.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

15.0K

Related Experiment Videos

Last Updated: Dec 24, 2025

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

15.0K

Area of Science:

  • Oncology
  • Medical Genetics
  • Cancer Research

Background:

  • The National Comprehensive Cancer Network (NCCN) guidelines recommend germline testing for pathogenic BRCA1/2 mutations found in somatic tumor sequencing.
  • This study investigates adherence to these guidelines at Stanford University.

Purpose of the Study:

  • To determine if patients with somatic BRCA1/2 mutations at Stanford were recommended for germline testing according to NCCN guidelines.
  • To identify factors associated with the recommendation for germline testing.

Main Methods:

  • Retrospective review of Stanford patients with BRCA1/2 mutations identified via tumor sequencing.
  • Analysis of medical records to identify germline testing recommendations.
  • Multivariable logistic regression to associate patient characteristics with testing recommendations.

Main Results:

  • Out of 164 participants, 51 (31.1%) did not receive a germline testing recommendation.
  • Among 97 patients with available results, 55.7% were positive for pathogenic BRCA1/2 mutations.
  • Patients with genitourinary, lung, sarcoma, skin, or other cancers were significantly less likely to be recommended for germline testing compared to those with breast or gynecological cancers.

Conclusions:

  • A significant proportion of patients with somatic BRCA1/2 mutations do not receive recommended germline testing.
  • There is a critical need for enhanced provider education, particularly outside of traditional breast and gynecological oncology specialties.
  • Further research into referral patterns for germline testing based on somatic findings is warranted.